Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015007 | PMC |
| http://dx.doi.org/10.4103/tcmj.tcmj_195_18 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cognitive effects of brief and intensive neurofeedback treatment in schizophrenia: a single center pilot study.
AIMS Neurosci
September 2024
Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.
Background: Schizophrenia is characterized by significant cognitive impairments and affects up to 98% of patients. Neurofeedback (NF) offers a means to modulate neural network function through cognitive processes such as learning and memorization, with documented structural changes in the brain, most notably an increase in grey matter volume in targeted regions.
Methods: The present 2-week, open-label, preliminary study aims to evaluate the efficacy on cognition of an adjunctive short and intensive (8 daily sessions lasting 30 minutes) alpha/theta NF training in a sample of subjects affected by schizophrenia on stabilized treatment with atypical antipsychotic drugs.
Generating Complex Explanations for Artificial Intelligence Models: An Application to Clinical Data on Severe Mental Illness.
Life (Basel)
June 2024
Department of Computer Science and Technology, University of Cambridge, Cambridge CB3 0FD, UK.
We present an explainable artificial intelligence methodology for predicting mortality in patients. We combine clinical data from an electronic patient healthcare record system with factors relevant for severe mental illness and then apply machine learning. The machine learning model is used to predict mortality in patients with severe mental illness.
View Article and Find Full Text PDFThe author reflects on a decade of antipsychotic treatment, providing an intimate glimpse into living with schizophrenia. Their narrative unravels the balance of vulnerability and strength, coercion, and dialogue inherent in the acceptance of medication. Their journey from defiance to adherence showcases the profound complexities patients face and the ethical dilemmas confronting caregivers.
View Article and Find Full Text PDFHaloperidol's introduction in the United States: A tale of a failed trial and its consequences.
J Hist Neurosci
March 2024
Unidade de Alcoologia de Lisboa, DICAD, ARSLVT, Lisbon, Portugal.
Haloperidol, the first butyrophenone neuroleptic, was created in Europe by Janssen Pharmaceuticals in 1958 and was introduced swiftly throughout the continent with great enthusiasm. On September 15, 1959, at Janssen's headquarters in Belgium, teams from around Europe praised the effectiveness of haloperidol. In the United States, on the contrary, its introduction was a tremendous failure, plagued by accusations of inefficacy and patent disputes.
View Article and Find Full Text PDFSerotonin 5-HT receptors in schizophrenia: Reflexions on an unfinished story.
Eur Neuropsychopharmacol
September 2023
Department of Physiology and Biophysics, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!